Literature DB >> 6810448

Incomplete fibrin formation and highly elevated Factor XIII activity in multiple myeloma.

H G Klingemann, R Egbring, K Havemann.   

Abstract

Bleeding is a common complication in patients suffering from multiple myeloma. In some cases a defect in fibrin formation has been suggested as one possible cause of haemorrhagic tendency. As shown in this investigation the defect in fibrin formation, ascertained using PAGE, is due to a lack of alpha-chain polymerization of fibrin monomers in 5/11 patients with IgG myeloma and in 2/5 patients with IgM paraproteinaemia. No disturbed fibrin polymerization could be observed in IgA myeloma (n = 6). Factor XIII concentrations of subunit A and to a lesser extent of subunit S (Laurell technique) were highly elevated in all cases with regular fibrin formation. comparable values were obtained by measuring the transamidase activity of factor XIII by incorporation of 14C-labelled purtrescin into casein. Levels up to 600% of normal could be recorded. In contrast, all patients with a lack of alpha-chain polymerization had a factor XIII activity within the normal range. Addition of factor XIII concentrate to plasma from patients with defective fibrin formation led in 5/8 cases to a partial cross-linking of alpha-monomers. we conclude that in some cases paraproteins can inhibit the factor XIII and prevent its action on fibrin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6810448     DOI: 10.1111/j.1600-0609.1981.tb00481.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  2 in total

1.  Immunohistochemical detection of factor XIIIa and factor XIIIs in synovial membranes of patients with rheumatoid arthritis or osteoarthritis.

Authors:  A Plenz; P Fritz; G König; W Laschner; J G Saal
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

2.  Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up.

Authors:  Philipp Stockmann; Eleftherios Vairaktaris; Falk Wehrhan; Martin Seiss; Stephan Schwarz; Bernd Spriewald; Friedrich-Wilhelm Neukam; Emeka Nkenke
Journal:  Support Care Cancer       Date:  2009-07-17       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.